Healthcare AI Company Market Map
Drug Discovery and Life Sciences AI
AI applied upstream of care delivery: target identification, molecule design, and precision medicine data platforms.
Buyer Brief
- Best-fit buyer
- Pharmaceutical R&D, biotechnology leadership, translational science, business development, and investors
- Primary use case
- Identify targets, design molecules, prioritize experiments, and connect biomedical data to research decisions
- Typical deployment
- Ranges from software and data partnerships to platform collaborations and internally owned drug pipelines
This category mixes software businesses, research partners, and drug developers. Comparing company value requires separating platform capability from pipeline ownership and clinical progress.
Companies in This Category
| Company | What it does | Stock or ownership | Research next |
|---|---|---|---|
| Tempus | Molecular data and precision medicine platform linking sequencing results to clinical records, used both at the point of oncology care and as a research data asset. | Direct listing: Nasdaq: TEM. | Company research Official site |
| Recursion | Drug discovery built on high-throughput cellular imaging and machine learning to map biological relationships, running its own internal pipeline rather than only selling software. | Direct listing: Nasdaq: RXRX. | Company research Official site |
| Isomorphic Labs | Alphabet spinout applying the protein structure prediction lineage of AlphaFold to drug design, working through pharmaceutical partnerships. | Public parent: Alphabet, Nasdaq: GOOGL and GOOG. | Company research Official site |
| Insilico Medicine | Generative chemistry and target discovery platform, notable for advancing AI-originated candidates into clinical trials rather than stopping at preclinical claims. | Direct listing: Hong Kong Stock Exchange: 03696. | Company research Official site |
| BenevolentAI | Knowledge-graph driven target identification, built on relationships extracted from biomedical literature and experimental data. | No current public listing. Shares were delisted from Euronext Amsterdam on March 13, 2025. | Company research Official site |
| Owkin | AI drug discovery and biomedical research company. Its K Pro platform combines research tools with patient data to support scientific analysis and drug development. | No current public listing was verified. | Company research Official site |
| Iterative Health | Iterative Health runs a network of community clinical trial sites and uses its own AI, called SKOUT, to read endoscopy and histology images and find patients who qualify for a study. Drug companies are the buyer, and gastroenterology and hepatology are its established areas, with cardiology and obesity being added. | No current public listing was verified. | Company research Official site |
| Chai Discovery | Chai Discovery builds AI models that predict how molecules stick to each other and design new antibodies from scratch. It sells those models to drug companies rather than developing medicines itself, and Eli Lilly, Pfizer, Novartis, argenx and Bristol Myers Squibb have all signed up to use them. | No current public listing was verified. | Company research Official site |
What to Verify Before Shortlisting
Evidence
- Which results are prospective, reproduced, and tied to a clinical or experimental endpoint?
- How many programs are AI-originated, AI-assisted, partnered, or internally owned?
- What has advanced beyond target identification and preclinical reporting?
Regulatory and workflow
- Which entity owns development, validation, and regulatory responsibility for each program?
- How are model-generated hypotheses reviewed before experimental or clinical use?
- What claims are about research productivity versus a regulated product?
Data and contracts
- Who owns generated molecules, targets, models, and derived data?
- Which proprietary datasets create defensibility and which are licensed?
- Can a partner reproduce outputs and export project data after the collaboration?
The question that matters: How much of the pipeline is AI-originated versus AI-assisted, and what has actually reached a clinical endpoint rather than a press release.
Directory inclusion is editorial and does not imply endorsement. Product capabilities, contracts, and regulatory status can change. Verify claims with the company and the relevant regulator before procurement.